electroCore Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting…

By Dr. Matthew Watson

ROCKAWAY, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the completion of patient enrollment in SAVIOR-1, a prospective, randomized, controlled study evaluating vagus nerve stimulation in patients who exhibit respiratory symptoms due to COVID-19. This study is being conducted at the Hospital Clínico Universitario de Valencia, Spain.

More here:
electroCore Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting...

Related Post


categoriaGlobal News Feed commentoComments Off on electroCore Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting… | dataFebruary 11th, 2021

About...

This author published 3752 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research